Brineura May Stop Progression in Typical, Atypical CLN2

Brineura May Stop Progression in Typical, Atypical CLN2

293713

Brineura May Stop Progression in Typical, Atypical CLN2

Brineura (cerliponase alfa) stabilized the progression of neuronal ceroid lipofuscinosis type 2 (CLN2) — a type of Batten disease — in a small group of people in Columbia, including those with an atypical onset that occurs later in childhood. Those results come from a small case series, “Real world effectiveness of cerliponase alfa in classical and atypical patients. A case series,” which was  published in the journal Molecular Genetics and Metabolism Reports.  Due to mutations…

You must be logged in to read/download the full post.